STAB

Biological preparations for use in cell cultures for medical purposes; preparations for detecting genetic predispositions for medical purposes; diagnostic reagents for medical use; chemical reagents for medical use; biological reagents for medical use; cells for medical use; living cells for medical use; antibodies for medical purposes; cell growth media for growing cells for medical or clinical use; cellular function activating agents for medical purposes; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; human and animal cells and related parts for medical use; viral vectors, for medical use; lentiviruses, lentivirus particles and lentivirus plasmids, for medical use; therapeutic preparations and substances for gene and cell therapy for medical use; gene therapy products, namely, genetically engineered tissues for transplant purposes; lentiviral vectors, for medical use; adeno-associated viral vectors, adenoviral vectors and non-viral vectors for the delivery of genes to cells, for medical use; immunotherapeutic agents for bacterial infections; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention of diseases of the immune system; all the aforesaid goods expressly excluding the following goods: substances and preparations for veterinary use; medicines and pharmaceuticals based on messenger RNA [mRNA]; pharmaceutical and medicinal preparations for use in the following fields: targeting messenger RNA (mRNA) and triggering its degradation; MRNA-based therapeutic preparations and therapeutic agents for the prevention and treatment in vivo, ex vivo or in situ of oncological diseases; MRNA-based therapeutic preparations and therapeutic agents for the prevention and treatment in vivo, ex vivo or in situ of tumors; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells.

Biological research; medical research services; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; gene therapy research; research and development in the field of microorganisms and cells; development of cell therapy products; product development in the following fields: immunotherapy; pharmaceutical drug development services in the following fields: cell therapy; pharmaceutical drug development services in the following fields: immunotherapy; development of gene-based medicines; design and development of medical technology in the following fields: cell therapy; design and development of medical technology in the following fields: immunotherapy; research and development of vaccines and medicines; consultancy relating to pharmaceutical research and development, in the following fields: cell therapy; consultancy relating to pharmaceutical research and development in the following fields: immunotherapy; research and development services in the field of antibodies; research and development services in the field of gene expression systems; laboratory services relating to the production of monoclonal antibodies; scientific services relating to the isolation and cultivation of human tissues and cells; research and development services in the field of immunology; research and development services in the field of cell therapy; research and development services in the field of immunotherapy; research and development of mRNA drugs.

Licensing authority services, in the following fields: cellular therapy; licensing authority services, in the following fields: immunotherapeutics; licensing of technology; licensing of intellectual property.